A phase II/III trial investigating the immunogenicity of early versus late immunisation with pneumococcal 7-valent CRM197 vaccine conjugate [Prevenar; Wyeth] + pneumococcal vaccine [polysaccharide 23-valent pneumococcal vaccine] in post-allogeneic stem cell transplant (SCT) patients.
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 13 Apr 2015
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Wyeth
- 28 Jan 2010 Secondary endpoint results published in Vaccine
- 15 Oct 2007 New trial record.